MOS
BMRN icon

MGO One Seven’s BioMarin Pharmaceuticals BMRN Stock Holding History

MGO One Seven’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-657
Closed -$55K – 554
2018
Q4 		$55K Buy
+657
New +$62.5K 0.02% 603
2018
Q1 		$6K Buy
76
+8
+12% +$687 ﹤0.01% 1245
2017
Q4 		$6K Buy
+68
New +$5.91K ﹤0.01% 1230

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MGO One Seven's BMRN Position: Q1 2019 in Review

MGO One Seven sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2019, closing a stake of 657 shares — an estimated $55K sold.

MGO One Seven first reported a position in BMRN in Q4 2017 and held it in 3 quarters. The position peaked at $55K in Q4 2018. 485 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

  • MGO One Seven reported no remaining BioMarin Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • MGO One Seven sold 657 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $55K.
  • MGO One Seven first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • MGO One Seven's BioMarin Pharmaceuticals position peaked at $55K in Q4 2018.
  • 485 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on MGO One Seven's 13F filing for Q1 2019, filed 9 Apr 2019.